Metastatic renal cell carcinoma Trials in Ann Arbor, United States
Conditions / Metastatic renal cell carcinoma / Ann Arbor, United States
Clinical trials for Metastatic renal cell carcinoma investigate a range of treatment strategies and patient populations.
16 total trials for this combination
Showing top 10 of 16 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT03055013 | Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy | ACTIVE_NOT_RECRUITING | — |
| NCT02231749 | Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) | COMPLETED | PHASE3 |
| NCT06500455 | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | RECRUITING | PHASE3 |
| NCT03595124 | A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05327686 | Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial | RECRUITING | PHASE2 |
| NCT03055013 | Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy | ACTIVE_NOT_RECRUITING | — |
| NCT04510597 | Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial | RECRUITING | PHASE3 |
| NCT04588246 | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery | TERMINATED | PHASE3 |
| NCT05935748 | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) | TERMINATED | PHASE2 |